ABSTRACT
Drug Utilization Study of Fondaparinux in Atrial Fibrillation Patients
(Study at ICCU and Ward of Cardiology Department of Dr. Soetomo
Surabaya General Hospital)

Riska Gustinawati

Background - One of the drugs therapy in Atrial Fibrillation (AF) is anticoagulant. Patients with intensive care or in the urgent condition need anticoagulant therapy that have rapid onset of action like UFH, LMWH or Fondaparinux. Fondaparinux has several potentially important advantages than UFH and LMWH: It is synthetic, no viral or other animal contaminants, a relatively long half-life, superior bioavailability, predictable dose effect, and does not have cross-reaction with heparin antibody.

Objectives – The aim of the study was to identify the utilizing of Fondaparinux in Atrial Fibrillation patients and Drug Related Problems (DRPs) according to using of this anticoagulant.

Methods - The analysis was conducted descriptively by using patients medical record (retrospective) which over the period January 2010 to December 2012 (3 years)

Results – From 14 patients who received Fondaparinux, 13 patients (93%) given administration 1 x 2.5 mg and 1 patient (7%) with 1 x 5 mg subcutaneously dose. The duration treatment of Fondaparinux was 2-7 days. No potentially drug interaction that occurred in 14 patients who received Fondaparinux with other drugs. Bleeding as a side effect of Fondaparinux was found in 1 patient who received Fondaparinux in this research. Fondaparinux should be effective as an anticoagulant if the aPTT value
showed range 1.5 – 2.5 x from normal value. From 14 patients, only 5 patients whose known their aPTT value. Out of all 5 patients there is only one who meet a demand of target therapy.

**Conclusion** – Drug Utilization of Fondaparinux in Dr. Soetomo General Hospital were according to European Society of Cardiology and American College of Chest Physicians Clinical Practice Guidelines Recommendations

**Keyword** : Drug Utilization Study, Fondaparinux, Atrial Fibrillation